Valneva SE (VLA):企業の財務・戦略的SWOT分析

◆英語タイトル:Valneva SE (VLA) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH456494FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:54
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Valneva SE (VLA) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Valneva SE (Valneva) is a biotechnology company that develops life-saving vaccines against infectious diseases and cancer. The company’s products include a vaccine indicated for the prevention of Japanese encephalitis and a vaccine indicated for the prevention of cholera and diarrhea. Its pipeline encompasses investigational candidates for the prevention of lyme, chikungunya, Zika virus, and infections caused by Clostridium difficile. The company works in partnership with various pharmaceutical and biopharmaceutical companies to develop its pipeline vaccine candidates and to distribute its products. The company sells its products in the Americas, Asia-Pacific, Europe, and the Middle East. It operates in Austria, Sweden, the UK, France, the US, and Canada. Valneva is headquartered in Saint-Herblain, France.

Valneva SE Key Recent Developments

Apr 07,2021: Valneva’s Covid-19 vaccine shows robust immune response in trial
Mar 24,2021: Valneva Publishes its FY 2020 Audited Consolidated Financial Statements
Mar 13,2021: Valneva Announces Supervisory Board Changes
Feb 25,2021: Valneva reports FY 2020 results and major corporate achievements
Jan 15,2021: Valneva announces amendment to Deerfield and OrbiMed debt facility terms

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Valneva SE – Key Facts
Valneva SE – Key Employees
Valneva SE – Key Employee Biographies
Valneva SE – Major Products and Services
Valneva SE – History
Valneva SE – Company Statement
Valneva SE – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Valneva SE – Business Description
Product Category: Dukoral
Overview
Performance
Key Stats
Product Category: Ixiaro/Jespect
Overview
Performance
Key Stats
Product Category: Lyme VLA15
Performance
Product Category: Other
Performance
Product Category: Third Party Products
Performance
Geographical Segment: Austria
Performance
Geographical Segment: Canada
Performance
Geographical Segment: Germany
Performance
Geographical Segment: Nordics
Performance
Geographical Segment: Other Europe
Performance
Geographical Segment: Rest of World
Performance
Geographical Segment: United Kingdom
Performance
Geographical Segment: United States
Performance
Valneva SE – Corporate Strategy
Valneva SE – SWOT Analysis
SWOT Analysis – Overview
Valneva SE – Strengths
Valneva SE – Weaknesses
Valneva SE – Opportunities
Valneva SE – Threats
Valneva SE – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Valneva SE, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Valneva SE, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Valneva SE, Recent Deals Summary
Section 5 – Company’s Recent Developments
Apr 07, 2021: Valneva’s Covid-19 vaccine shows robust immune response in trial
Mar 24, 2021: Valneva Publishes its FY 2020 Audited Consolidated Financial Statements
Mar 13, 2021: Valneva Announces Supervisory Board Changes
Feb 25, 2021: Valneva reports FY 2020 results and major corporate achievements
Jan 15, 2021: Valneva announces amendment to Deerfield and OrbiMed debt facility terms
Jan 11, 2021: Valneva strengthens management team; appoints Perry Celentano as interim COO and David Lawrence as acting CFO
Jan 07, 2021: Valneva reports FY 2020 cash of over €200 million
Nov 03, 2020: Valneva reports nine month results marked by further major corporate achievements
Sep 18, 2020: Valneva announces retirement of chief financial officer David Lawrence
Aug 06, 2020: Valneva announces appointment of Juan Carlos Jaramillo as Chief Medical Officer
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Valneva SE, Key Facts
Valneva SE, Key Employees
Valneva SE, Key Employee Biographies
Valneva SE, Major Products and Services
Valneva SE, History
Valneva SE, Subsidiaries
Valneva SE, Key Competitors
Valneva SE, Ratios based on current share price
Valneva SE, Annual Ratios
Valneva SE, Annual Ratios (Cont...1)
Valneva SE, Annual Ratios (Cont...2)
Valneva SE, Interim Ratios
Valneva SE, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Valneva SE, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Valneva SE, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Valneva SE (VLA):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Incitec Pivot Ltd (IPL):企業の財務・戦略的SWOT分析
    Incitec Pivot Ltd (IPL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Grainger Plc (GRI):企業の財務・戦略的SWOT分析
    Grainger Plc (GRI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • LIG Nex1 Co., Ltd.:企業の戦略・SWOT・財務情報
    LIG Nex1 Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary LIG Nex1 Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Elite Surgical Supplies (Pty) Ltd:製品パイプライン分析
    Summary Elite Surgical Supplies (Pty) Ltd (Elite Surgical) is a medical device company that manufactures and distributes surgical instruments. The company provides spinal, arthoplasty and consumable surgical instruments. Its spinal products include stand alone equipment, cervical cage, boiling VBR, …
  • Can-Fite BioPharma Ltd (CANF):企業の財務・戦略的SWOT分析
    Summary Can-Fite BioPharma Ltd (Can-Fite) is a clinical stage drug development Company that strives to develop small molecule drugs for the treatment of cancer and inflammatory diseases. The company’s pipeline products which are in phase II and III clinical development stage includes CF101, for rheu …
  • Piller Group GmbH:企業の戦略的SWOT分析
    Piller Group GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • HeartWare International Inc:企業の戦略的SWOT分析
    HeartWare International Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Avid Technology Inc (AVID):企業の財務・戦略的SWOT分析
    Avid Technology Inc (AVID) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Geron Corp (GERN)-製薬・医療分野:企業M&A・提携分析
    Summary Geron Corp (Geron) is a clinical stage biopharmaceutical company, which develops a telomerase inhibitor as a potential treatment for cancer. The company is evaluating its flagship product candidate Imetelstat in two clinical trials: IMbark and IMerge in partnership with Janssen Biotech, Inc. …
  • BRF SA:戦略・SWOT・企業財務分析
    BRF SA - Strategy, SWOT and Corporate Finance Report Summary BRF SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, prov …
  • Dirk Rossmann GmbH:企業の戦略・SWOT・財務情報
    Dirk Rossmann GmbH - Strategy, SWOT and Corporate Finance Report Summary Dirk Rossmann GmbH - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Advanced Sterilization Products Services Inc:製品パイプライン分析
    Summary Advanced Sterilization Products Services Inc (ASP) is a healthcare service provider that offers infection prevention solutions and educational programs for healthcare facilities. The company offers products such as medical device sterilization systems, high-level disinfection products and de …
  • Cyclopharm Ltd (CYC):企業の財務・戦略的SWOT分析
    Cyclopharm Ltd (CYC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Turkiye Petrol Rafinerileri AS (TUPRS):企業の財務・戦略的SWOT分析
    Turkiye Petrol Rafinerileri AS (TUPRS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Bayer AG (BAYN)-医療機器分野:企業M&A・提携分析
    Summary Bayer AG (Bayer) carries out the research, development, production and commercialization of products in the areas of human and animal health care, and agriculture. It provides pharmaceuticals for cardiology, women’s healthcare, oncology, hematology, ophthalmology, infection and other indicat …
  • TransUnion LLC:企業の戦略・SWOT・財務分析
    TransUnion LLC - Strategy, SWOT and Corporate Finance Report Summary TransUnion LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Cerner Corporation:企業の戦略・SWOT・財務情報
    Cerner Corporation - Strategy, SWOT and Corporate Finance Report Summary Cerner Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Upstream Medical Technologies Ltd:企業の製品パイプライン分析2018
    Summary Upstream Medical Technologies Ltd (UMT) is a biomarker based testing developer that markets novel biomarkers for cardiac diagnosis. The company offers patented pipeline of products such as BNP-sp, used for diagnoses of unstable angina, CVD, ACS, and others. It provides pipe line product such …
  • tella Inc (2191):製薬・医療:M&Aディール及び事業提携情報
    Summary Tella Inc (Tella) is a drug development company that develops vaccines for cancer treatment. The company offers dendritic cell vaccine therapy which develops dendritic cells to convey the information on cancer markers to lymphocytes and increase the dendritic cell population and strengthen t …
  • Tox Free Solutions Limited (TOX):企業の財務・戦略的SWOT分析
    Tox Free Solutions Limited (TOX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆